Yan, Jingyue
Kang, Diana D.
Wang, Chang
Hou, Xucheng
Du, Shi
Wang, Siyu
Xue, Yonger
Liu, Zhengwei
Li, Haoyuan
Zhong, Yichen
Deng, Binbin
McComb, David W.
Dong, Yizhou
Article History
Received: 28 February 2024
Revised: 6 May 2024
Accepted: 11 May 2024
First Online: 27 June 2024
Ethics
: <b>Conflicts of interest</b> Yizhou Dong is a scientific advisory board member and holds equity in Arbor Biotechnologies and Sirnagen Therapeutics. Yizhou Dong is a co-founder and holds equity in Immunanoengineering Therapeutics. Other authors have no competing interests to declare.